NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. ( SLS) ("SELLAS" or the Company), a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications, today announced encouraging updated clinical data from a Phase 1 investigator-sponsored clinical trial of its lead clinical candidate, galinpepimut-S (GPS), combined with the checkpoint inhibitor nivolumab (Opdivo) in patients with malignant pleural mesothelioma (MPM) who were either refractory to or relapsed after at least one line of the standard of care therapy.
Data from eight patients enrolled in the study have been analyzed, with final data in the clinical trial expected by the end of 2022. Of the eight patients, seven received at least three doses of GPS, the last of which was given in combination with nivolumab. All enrolled patients have received and progressed with, or were refractory to, frontline pemetrexed-based chemotherapy.
The study details are as follows:
This updated data is very encouraging, as it not only confirms our data reported in June 2021, but now reflects an increased survival benefit even though almost all additionally enrolled patients had Grade III and IV malignant mesothelioma, said Angelos Stergiou, M.D., Sc.D. h.c., President and CEO, SELLAS. This increase in survival appears to be consistent with long term immunity-mediated antitumor effect with this immunotherapy combination and it reinforces the data we unveiled earlier this year from the Phase 1/2 clinical trial of GPS in combination with another checkpoint inhibitor, pembrolizumab, in relapsed and refractory ovarian cancer patients, in which GPS showed a superior disease control rate compared to that seen with checkpoint inhibitors alone.
Of additional importance is the fact that both trials addressed patients with bulky active disease, the setting in which other cancer vaccines have historically had very little effect. We believe that the results of both studies demonstrate the potential effectiveness of GPS as a combination therapy, concluded Dr. Stergiou.
About MPMWith approximately 3,300 cases in the United States each year, accompanied by a rising incidence in developing countries, MPM is notoriously difficult to treat and can lead to poor clinical outcomes with respect to both OS and PFS, especially for those patients with the sarcomatoid variant who show a median OS of approximately 4.0 to 5.0 months. In relapsed and refractory patients who progressed after the first line standard of care pemetrexed, a similar patient population to that in the GPS nivolumab combination trial, the common treatment regimen is vinorelbine and OS in those patients is reported to be between 4.5 and 6.2 months. In patients treated with other chemotherapy regimens, such as carboplatin and irinotecan, median OS is reported to be approximately 7.0 months.
About SELLAS Life Sciences Group, Inc.SELLAS Life Sciences Group, Inc. ( SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.
For more information on SELLAS, please visit http://www.sellaslifesciences.com.
Opdivo is a registered trademark of Bristol Myers Squibb, and is not a trademark of SELLAS. The manufacturer of this brand is not affiliated with and does not endorse SELLAS or its products.
Forward-Looking StatementsThis press release contains forward-looking statements. All statements other than statements of historical facts are forward-looking statements, including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as plan, expect, anticipate, may, might, will, should, project, believe, estimate, predict, potential, intend, or continue and other words or terms of similar meaning. These statements include, without limitation, statements related to the clinical development of GPS for MPM, and the potential for GPS as a drug development candidate. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Companys clinical plans, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption Risk Factors in SELLAS Annual Report on Form 10-K filed on March 31, 2022 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
Investor ContactAllison SossKCSA Strategic CommunicationsEmail: [emailprotected]Phone: 212.896.1267
Media ContactsRaquel Cona / Michaela FawcettKCSA Strategic CommunicationsEmail: [emailprotected]Phone: 212.896.1204
The rest is here:
- Diagnosing Pleural Mesothelioma with Lung Fluid: The Battle of the Biomarkers - Surviving Mesothelioma - March 24th, 2017 [March 24th, 2017]
- Republican Health Care Bill Includes Asbestos Exposure Funding for Libby Residents - Mesothelioma.com - March 24th, 2017 [March 24th, 2017]
- Pembrolizumab shows promise in treatment of mesothelioma - Science Daily - March 24th, 2017 [March 24th, 2017]
- Veterans with Mesothelioma Benefit from Telephone Triage - Asbestos.com - March 24th, 2017 [March 24th, 2017]
- Mesothelioma Survival Rates Slowly Improving - Mesothelioma.net Blog (blog) - March 24th, 2017 [March 24th, 2017]
- Understanding Mesothelioma Caregiver Styles - Asbestos.com (blog) - March 24th, 2017 [March 24th, 2017]
- Mesothelioma Patients Turn to Cannabis - AlterNet - March 24th, 2017 [March 24th, 2017]
- Mesothelioma | Overview, Treatment Options and Survivor Stories - March 24th, 2017 [March 24th, 2017]
- Accelerated Approval Granted to Drug in Mesothelioma Research Pipeline - MesotheliomaHelp.org (blog) - April 8th, 2017 [April 8th, 2017]
- New Study Affirms Mesothelioma Survival Benefit with Post-Surgical IMRT, According to Surviving Mesothelioma - Benzinga - April 8th, 2017 [April 8th, 2017]
- The Key to Mesothelioma Treatment Success with Immunotherapy - Surviving Mesothelioma - April 8th, 2017 [April 8th, 2017]
- New Evidence Supports Post-Surgical IMRT for Mesothelioma Treatment - Surviving Mesothelioma - April 8th, 2017 [April 8th, 2017]
- Shorter Mesothelioma Survival Linked to High Platelet Count - Asbestos.com - April 8th, 2017 [April 8th, 2017]
- Mesothelioma Victims Center Now Appeals to All Diagnosed ... - Yahoo Finance - April 8th, 2017 [April 8th, 2017]
- Early research suggests first immunotherapy for mesothelioma on the horizon - Medical Xpress - June 6th, 2017 [June 6th, 2017]
- Bristol-Myers Squibb's Opdivo, Yervoy put the brakes on mesothelioma in phase 2 - FiercePharma - June 6th, 2017 [June 6th, 2017]
- Methanol from African Plants Kills Mesothelioma Cells - Asbestos.com - June 6th, 2017 [June 6th, 2017]
- Mesothelioma Patients to be Celebrated on National Cancer Survivor's Day - Mesothelioma.net Blog (blog) - June 6th, 2017 [June 6th, 2017]
- IO Strategy In Mesothelioma Finally Gets Mapped Out | Seeking Alpha - Seeking Alpha - June 6th, 2017 [June 6th, 2017]
- New Blood Test Could Mean Earlier Mesothelioma Diagnosis - Surviving Mesothelioma - June 6th, 2017 [June 6th, 2017]
- Using Viruses to Boost Mesothelioma Immunotherapy - Asbestos.com - June 6th, 2017 [June 6th, 2017]
- Resilience Can Help Mesothelioma Patients and Their Families ... - MesotheliomaHelp.org (blog) - June 7th, 2017 [June 7th, 2017]
- Janet Stanton Schnitzer Remembers Her Father's Mesothelioma Battle - Mesothelioma & Asbestos Awareness Center (blog) - June 7th, 2017 [June 7th, 2017]
- Treating Mesothelioma: A rare, aggressive caner - ABC2 News - June 7th, 2017 [June 7th, 2017]
- Asbestos and Mesothelioma Lawsuits: What to Expect | Nolo.com - June 7th, 2017 [June 7th, 2017]
- Mesothelioma Victims Center Now Urges a Roofer/Insulator With Mesothelioma to Call About Why It Is Necessary to ... - PR Newswire (press release) - June 9th, 2017 [June 9th, 2017]
- Mesothelioma Patients May Have Another Treatment Option With FDA Expanded-Use Approval of Lung Cancer Drug - MesotheliomaHelp.org (blog) - June 9th, 2017 [June 9th, 2017]
- A Breath Test for Mesothelioma? - Surviving Mesothelioma - June 9th, 2017 [June 9th, 2017]
- Mesothelioma Cancer: 12 Essential Facts - Asbestos News - June 9th, 2017 [June 9th, 2017]
- Mesothelioma - NHS Choices - June 9th, 2017 [June 9th, 2017]
- 15-year Mesothelioma Survivor Living Life By Design - Asbestos.com (blog) - June 9th, 2017 [June 9th, 2017]
- Mesothelioma Cancer Overview | Experienced Lawyers Here to Help - June 11th, 2017 [June 11th, 2017]
- Mesothelioma Victims Center Now Urges a Diagnosed Machinist to Call for Direct Access to Journeyman-Level ... - PR Newswire (press release) - June 12th, 2017 [June 12th, 2017]
- Honeywell Fails in Appeal Against Mesothelioma Verdict - Mesothelioma.net Blog (blog) - June 12th, 2017 [June 12th, 2017]
- Mesothelioma Patients Can See Improved Survival By Reporting Side Effects - MesotheliomaHelp.org (blog) - June 12th, 2017 [June 12th, 2017]
- What is Mesothelioma? | Surviving Mesothelioma - Surviving Mesothelioma - June 13th, 2017 [June 13th, 2017]
- Cases of Pleural Mesothelioma - Surviving Mesothelioma - June 13th, 2017 [June 13th, 2017]
- The Importance of Cancer Research in Immunotherapy - Mesothelioma.com (blog) - June 14th, 2017 [June 14th, 2017]
- Hopes High for Mesothelioma Immunotherapy Treatment ... - Mesothelioma.net Blog (blog) - June 14th, 2017 [June 14th, 2017]
- Asbestos Sprayers Face Higher Lifetime Mesothelioma Risk ... - Surviving Mesothelioma - June 14th, 2017 [June 14th, 2017]
- Remembering Loved Ones Lost to Mesothelioma, Looking Forward to Progress in Treatment - MesotheliomaHelp.org (blog) - June 14th, 2017 [June 14th, 2017]
- Chicago Public Schools Ignoring Asbestos Problem - Mesothelioma.com - June 16th, 2017 [June 16th, 2017]
- Length of Time Between Surgeries a Marker for Mesothelioma Survival - Surviving Mesothelioma - June 16th, 2017 [June 16th, 2017]
- Mesothelioma Survivor Deals with Pain 15 Years After Surgery - Asbestos.com (blog) - June 16th, 2017 [June 16th, 2017]
- Nivolumab and Ipillimumab Show Promise in Treating Mesothelioma Recurrence - Mesothelioma.com - June 16th, 2017 [June 16th, 2017]
- Mesothelioma Patients Should Heed FDA Warnings Regarding Miracle Cures - MesotheliomaHelp.org (blog) - June 16th, 2017 [June 16th, 2017]
- Mesothelioma Patients May Benefit from Marijuana Research - Mesothelioma.net Blog (blog) - June 17th, 2017 [June 17th, 2017]
- The Challenges of Research in Immunotherapy - Mesothelioma.com (blog) - June 17th, 2017 [June 17th, 2017]
- Despite Mesothelioma Diagnosis, Dad Loved Father's Day - Asbestos.com (blog) - June 17th, 2017 [June 17th, 2017]
- I Want to Keep Writing About Mesothelioma and My Family's Journey Because It Matters - MesotheliomaHelp.org (blog) - June 17th, 2017 [June 17th, 2017]
- Mesothelioma Clinical Trial Opens with High Expectations - Asbestos.com - June 17th, 2017 [June 17th, 2017]
- Cediranib May be Safe Supplement to Mesothelioma Treatment - Surviving Mesothelioma - June 17th, 2017 [June 17th, 2017]
- New Trial Finds VEGF-Inhibitor May Safely Boost Mesothelioma ... - Benzinga - June 18th, 2017 [June 18th, 2017]
- Mesothelioma Symptoms - Identify Early Warning Signs - June 18th, 2017 [June 18th, 2017]
- Mesothelioma Victims Center Now Urges a Diagnosed Construction Worker or Plumber to Call for Instant Access to the ... - PR Newswire (press release) - June 20th, 2017 [June 20th, 2017]
- Mesothelioma Treatment May Benefit From New Discovery ... - Mesothelioma.net Blog (blog) - June 20th, 2017 [June 20th, 2017]
- The Influence of BAP1 on Mesothelioma Survival - Surviving Mesothelioma - June 20th, 2017 [June 20th, 2017]
- Clinical Trial to Assess If Radiation Therapy Can Bring Effective Relief from Mesothelioma Pain - MesotheliomaHelp.org (blog) - June 20th, 2017 [June 20th, 2017]
- Asbestos Exposure Attorneys - Mesothelioma Lawsuits ... - June 20th, 2017 [June 20th, 2017]
- Can a Breath Test Diagnose Mesothelioma in the Early Stages? - Asbestos.com - June 21st, 2017 [June 21st, 2017]
- Mesothelioma Compensation Center Now Urges an Electric Utility Worker or Electrician with Mesothelioma to Aim High ... - PR Newswire (press release) - June 21st, 2017 [June 21st, 2017]
- Nurse Explains Mesothelioma Staging - MesotheliomaHelp.org (blog) - June 21st, 2017 [June 21st, 2017]
- 5 Questions: Treatment options exist for mesothelioma - Las Vegas Review-Journal - June 21st, 2017 [June 21st, 2017]
- Steve McQueen's Wife Pushes for Asbestos Ban - Mesothelioma.com - June 21st, 2017 [June 21st, 2017]
- Remembering Mesothelioma Victims in the UK - Mesothelioma.com (blog) - June 21st, 2017 [June 21st, 2017]
- Peritoneal Cancer Index: What it Means for Mesothelioma Patients - Mesothelioma & Asbestos Awareness Center (blog) - June 21st, 2017 [June 21st, 2017]
- Mesothelioma Risk Continues to Rise for Decades After Asbestos Exposure - Surviving Mesothelioma - June 21st, 2017 [June 21st, 2017]
- Nintedanib Combination Delayed Progression in Malignant Mesothelioma - Cancer Network - June 22nd, 2017 [June 22nd, 2017]
- Polish Study Confirms That Mesothelioma Risk Only Increases With ... - Mesothelioma.net Blog (blog) - June 22nd, 2017 [June 22nd, 2017]
- The Mesothelioma Victims Center Now Urges a Diagnosed Navy ... - PR Newswire (press release) - June 22nd, 2017 [June 22nd, 2017]
- Targeted Therapy May Soon be Primary Approach for Mesothelioma Treatment - MesotheliomaHelp.org (blog) - June 23rd, 2017 [June 23rd, 2017]
- Time Between Surgeries Helps Predict Mesothelioma Survival - Asbestos.com - June 23rd, 2017 [June 23rd, 2017]
- Testicular and Cardiac Mesothelioma - Surviving Mesothelioma - June 23rd, 2017 [June 23rd, 2017]
- Mesothelioma Veterans Center - Access Benefits & VA Claims - June 23rd, 2017 [June 23rd, 2017]
- Malignant Mesothelioma (Asbestos Cancer) > The Mesothelioma ... - June 23rd, 2017 [June 23rd, 2017]
- Mesothelioma Law Firm | Sokolove Law - June 23rd, 2017 [June 23rd, 2017]
- MicroRNAs May Be Key to Better Immunotherapy for Mesothelioma - Surviving Mesothelioma - June 24th, 2017 [June 24th, 2017]
- Mesothelioma Survival Rate | Factors Affecting Survivorship - June 24th, 2017 [June 24th, 2017]
- Scientists "Turn Off" Tumor-Protecting Protein in New Mesothelioma Study, According to Surviving Mesothelioma - Benzinga - June 26th, 2017 [June 26th, 2017]
- Symptoms of Mesothelioma - Critical Signs to Watch For - June 26th, 2017 [June 26th, 2017]